CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Hold” from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned an average recommendation of “Hold” from the nineteen research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $75.63.

A number of equities research analysts recently weighed in on CRSP shares. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Royal Bank of Canada reduced their price target on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 6th. Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday, June 28th. Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, May 23rd. Finally, Needham & Company LLC reduced their target price on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, August 6th.

CRISPR Therapeutics Trading Down 0.6 %

Shares of CRSP stock opened at $49.59 on Thursday. The firm has a fifty day moving average price of $50.79 and a 200 day moving average price of $57.45. The company has a market cap of $4.21 billion, a P/E ratio of -18.23 and a beta of 1.68. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $12.31 million. During the same period in the previous year, the business posted ($0.98) earnings per share. CRISPR Therapeutics’s revenue was down 99.3% compared to the same quarter last year. On average, equities analysts forecast that CRISPR Therapeutics will post -5.6 EPS for the current year.

Insider Buying and Selling

In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nordea Investment Management AB grew its position in CRISPR Therapeutics by 40.8% during the first quarter. Nordea Investment Management AB now owns 148,700 shares of the company’s stock worth $10,305,000 after buying an additional 43,100 shares during the period. Congress Asset Management Co. MA grew its position in CRISPR Therapeutics by 60.3% during the first quarter. Congress Asset Management Co. MA now owns 64,605 shares of the company’s stock worth $4,403,000 after buying an additional 24,303 shares during the period. PBCay One RSC Ltd acquired a new position in CRISPR Therapeutics during the fourth quarter worth about $10,329,000. Cetera Investment Advisers grew its position in CRISPR Therapeutics by 451.3% during the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock worth $2,324,000 after buying an additional 27,915 shares during the period. Finally, CWM LLC grew its position in CRISPR Therapeutics by 11,871.1% during the second quarter. CWM LLC now owns 22,386 shares of the company’s stock worth $1,209,000 after buying an additional 22,199 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.